A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis

Phase 1

• Conditions: multiple sclerosis; MedDRA version: 15.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2011-001437-16-DE
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-09
• Study Completion: 2017-08-07
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 422

Inclusion Criteria

Patients eligible for inclusion in this study have to fulfill the following criteria:
• Written informed consent must be obtained before any assessment is performed
• Male and female patients aged 18-55 years inclusive
• A diagnosis of MS as defined by the 2005 revision to the McDonald criteria with a relapsingremitting
course
• MS disease duration of more than one year (from diagnosis of MS) before study entry (Screening) Participants of the reference group eligible for inclusion have to fulfill the following criteria:
• Written informed consent must be obtained before any assessment is performed
• Male and female subjects aged 18-55 years inclusive
• Matched to MS patients recruited in terms of age (±3 years),
ethnicity, gender and visual refraction (±2 diopters) with the MS patients recruited.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 420
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
2. Any ophthalmologic reason for RNFL pathology other than MS, such as: optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia: a. in patients who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in patients that have had previous refractive surgery, an axial eye length of greater than 26 mm
3. Acute optic neuritis within the past 6 months before Baseline
4. Evidence of advanced, non-proliferative or proliferative diabetic retinopathy
5. Presence of retinal conditions associated with edema, subretinal fluid, cysts, etc.
6. History of a severe head trauma
7. Any of the following neurologic/psychiatric disorders:
• history of substance abuse (drug or alcohol) in the past five years or any other factor (i.e., serious psychiatric condition) that may interfere with the subject’s ability to cooperate and comply with the study procedures • specific MRI findings (tumor, subdural haematoma, post-contusional changes, territorial stroke, neurodegenerative disorders, aneurysm/arteriovenous malformation, evidence of past macroscopic haemorrhage, or other relevant MRI findings that would interfere with evaluation) • progressive neurological disorder, other than MS, which may affect participation in the study
8. Concomitant use of drugs that may directly affect retinal structure and function (e.g. chronic systemic corticosteroids [>30 consecutive days; doses higher than Cushing threshold e.g. prednisone 7.5mg/d], intraocular anti-angiogenic drugs [ranibizumab, bevacizumab], intraocular steroids etc.)
9. Any medically unstable condition, progressive disease (other than MS) or other condition that would preclude reliable participation in the study as assessed by the investigator
10. Patients unable to undergo MRI scans including gadolinium enhancement:
• reduced renal clearance (eGFR <45 ml/min) • history of severe hypersensitivity to gadolinium-DTPA • claustrophobia that cannot be overcome otherwise
11. Patients who have received an investigational drug or therapy within 30 days or 5 half lives, which ever is longer, of the baseline visit. No additional exclusions may be applied by the investigator, in order to ensure that the population will be representative of all eligible patients. Participants of the reference group fulfilling any of the following criteria are not eligible for inclusion in this study:
1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
2. Any ophthalmologic reason for RNFL pathology other than MS, such as: • optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia:
a. in subjects who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in subjects that have had previous refractive surgery, an axial eye length of greater than 26 mm
3. Acute optic neuritis within the past 6 months before Baseline
4. Evidence of advanced, non-proli

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified